Compass Therapeutics (NASDAQ:CMPX) Downgraded by Lifesci Capital to Hold

Lifesci Capital downgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a strong-buy rating to a hold rating in a research report report published on Tuesday morning,Zacks reports.

A number of other brokerages also recently weighed in on CMPX. Wall Street Zen downgraded Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Wedbush set a $4.00 target price on shares of Compass Therapeutics in a research note on Wednesday. Guggenheim dropped their target price on shares of Compass Therapeutics to $4.00 and set a “buy” rating on the stock in a report on Wednesday. Stifel Nicolaus set a $6.00 price target on shares of Compass Therapeutics in a report on Monday, June 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Compass Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.21.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $1.17 on Tuesday. Compass Therapeutics has a one year low of $1.13 and a one year high of $6.88. The company’s 50-day simple moving average is $2.12 and its 200-day simple moving average is $2.93. The stock has a market capitalization of $210.71 million, a price-to-earnings ratio of -2.92 and a beta of 0.95.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, research analysts forecast that Compass Therapeutics will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Compass Therapeutics during the 2nd quarter valued at about $24,707,000. BVF Inc. IL lifted its position in shares of Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock worth $41,697,000 after purchasing an additional 3,014,842 shares in the last quarter. Palo Alto Investors LP acquired a new stake in shares of Compass Therapeutics during the second quarter worth approximately $12,771,670. Sofinnova Investments Inc. boosted its holdings in shares of Compass Therapeutics by 65.9% during the fourth quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company’s stock worth $18,072,000 after purchasing an additional 1,336,560 shares during the period. Finally, NEXTBio Capital Management LP purchased a new position in Compass Therapeutics during the fourth quarter valued at approximately $5,982,000. 68.43% of the stock is owned by institutional investors.

More Compass Therapeutics News

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Citizens JMP maintained a Market Outperform rating but lowered its price target to $4.00. The target implies substantial potential upside if Compass successfully addresses regulatory concerns and advances tovecimig toward approval.
• Positive Sentiment: Compass said it intends to continue pursuing the program despite the FDA feedback, signaling that management believes tovecimig remains commercially viable and that the additional regulatory requirements can be addressed. Compass vows to press on with FDA application despite new trial request
• Neutral Sentiment: Analysts and commentary described tovecimig as having a promising opportunity in biliary tract cancer, but warned that the development and regulatory window is becoming narrower, increasing execution risk. Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
• Negative Sentiment: The FDA recommended that Compass conduct a trial demonstrating a survival benefit in previously treated, advanced biliary tract cancer before submitting a Biologics License Application. This could materially delay a potential filing, raise development costs and require additional financing. Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
• Negative Sentiment: Wedbush downgraded CMPX from Outperform to Neutral and cut its price target to $1 from $5, citing the FDA’s additional-trial request and estimating further downside. LifeSci Capital also downgraded the stock to Hold. Wedbush Downgrades Compass Therapeutics

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.